AB002 / AKSO Biopharma, Huadong Medicine - LARVOL DELTA

AKSO and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize AB002 in Asia Pacific Ex-Japan (Businesswire) - "AKSO Biopharmaceutical...and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., ...announced that the companies have entered into an exclusive collaboration to develop and commercialize AB002, a bi-functional fusion protein inhibiting immune checkpoint and activating natural killer (NK) cells for the treatment of solid tumors, in the Asia Pacific Ex-Japan region. AKSO will retain all rights to AB002 in the rest of the world....Under the terms of the agreement, AKSO will be eligible to receive upfront and milestone payments of up to $75 million, as well as royalties from future product sales."

Licensing / partnership • Oncology • Solid Tumor